PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Disease ReportsSystemic mastocytosis
MeSH D034721 - systemic mastocytosis
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D008415:Mastocytosis
$
Success rate
D034721: 
Systemic mastocytosis
$
Success rate
D007946:Mast-cell leukemia
0 Companies
0 Drugs
Success rate
Events Timeline
Loading
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
TevaImatinib Imatinib  2016-08-04   
Imatinib Imatinib Teva  2013-01-07   
Imatinib Imatinib Teva B.V  2017-11-15   
MylanImatinib Imatinib  2017-06-21   
NovartisImatinib Gleevec  2001-05-10 $887 M Q2/20-Q2/23 
Imatinib Glivec  2001-11-07   
Midostaurin Rydapt 2022-10-29 2017-04-28   
Dr Reddys LaboratoriesImatinib Imatinib  2018-08-13   
Zydus TherapeuticsImatinib Imatinib  2020-04-08   
Sun Pharmaceutical IndustriesImatinib Imatinib  2015-12-03   
ApotexImatinib Imatinib  2016-08-05   
Breckenridge PharmaceuticalImatinib Imatinib  2019-02-08   
Amneal PharmaceuticalsImatinib Imatinib  2019-02-08   
NATCO PharmaImatinib Imatinib  2019-03-01   
1
2
>
Clinical Trials
Historical Success Rate
Phase 1
17%
3/18
Phase 2
17%
2/12
Phase 3
40%
2/5
Approved: 2Overall Success rate: 1%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
Teva
1
2
>
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use